Skip to main content
SpringerLink
Log in

Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells

  • Chapter
Molecular and Cellular Biology of Prostate Cancer

Abstract

During this year there will be approximately 30 thousand deaths due to prostatic cancer in the United States (1). This mortality rate makes prostatic cancer the second commonest fatal tumor in males of all ages in America, and the leading cause of cancer death in men over the age of 55 (1). Besides a high annual mortality rate, prostatic cancer is now the most commonly diagnosed malignancy in males of all ages in the United States (1). These high annual incidence rates translate into the human reality that one of every 12 American white males will eventually develop clinical prostatic cancer during their lifetimes (2). Rates for American black males are even higher such that the lifetime risk for cancer is one out of every 10 (3). In addition, the annual incidence rate of clinical prostatic cancer has increased steadily since 1930 to the present time (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silverberg, E., Lubera, J.A. Cancer Statistics, 1989. CA-Cancer Journal for Clinicians. 39:3–20, 1989.

    Article  CAS  Google Scholar 

  2. Seidman, H., Mushinski, M.H., Gelb, S.K., Silverberg, E. Probabilities of eventually developing or dying of cancer: United States. CA-Cancer Journal for Clinicians, 35:36–56, 1985.

    Article  CAS  Google Scholar 

  3. Mettlin, G. Epidemiology of prostate cancer in different population groups. Clinics in Oncology, 2:287–300, 1983.

    Google Scholar 

  4. Young, J.L., Percey, C.L. and Asire, A.J. Surveillance, epidemiology and end results: incidence and mortality data, 1973-1977. National Cancer Institute Monograph 57, DHHS Publication No. (NIH) 81–2330. 1981.

    Google Scholar 

  5. Scott, W.W., Menon, M., Walsh, P.C. Hormonal therapy of prostatic cancer. Cancer, 45:1929–1936, 1980.

    CAS  PubMed  Google Scholar 

  6. Schulze, H., Isaacs, J.T., Coffey, D.S. A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. IN Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C., Denis, L. (eds.). Prostate cancer part a: research endocrine treatment, and histopathology progress in clinical and biological research. Vol. 243A pp 1–19. Alan R. Liss, Inc., New York, 1987.

    Google Scholar 

  7. Smith, J.A., Eyse, H.J., Roberts, T.S., Middleton, R.G. Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer, 53:2385–2387, 1984.

    Article  PubMed  Google Scholar 

  8. Menon, M., Walsh, P.C. Hormonal therapy for prostatic cancer. In Murphy, G.P. (ed). Prostatic Cancer, Littleton Mass, PSG Publ. Co., pp 175–200, 1979.

    Google Scholar 

  9. Devese, S.S., Silverman, D.T. Cancer incidence and morbidity trends in the United States: 1935-1974. J. Natl. Cancer Inst., 60:545–571, 1978.

    Google Scholar 

  10. Lepor, H., Ross, A., Walsh, P.C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol., 128:335–340, 1982.

    CAS  PubMed  Google Scholar 

  11. Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in Oncology, 15:371–389, 1988.

    CAS  PubMed  Google Scholar 

  12. Prout, G.R., Leiman, B., Daly, J.J., MacLoughlin, R.A., Griffin, P.P., Young, H.H. Endocrine changes after diethylstilbestrol therapy. Urology, 7:148–155, 1976.

    Article  CAS  PubMed  Google Scholar 

  13. Sinha, A.A., Blackard, C.E., Seal, U.S. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer, 40:2836–2850, 1977.

    Article  CAS  PubMed  Google Scholar 

  14. Smolev, J.K., Heston, W.D.W., Scott, W.W., Coffey, D.S. An appropriate animal model for prostatic cancer. Cancer Treat Rep., 61:273–287, 1977.

    CAS  PubMed  Google Scholar 

  15. Isaacs, J.T., Coffey, D.S. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res., 41:5070–5075, 1981.

    CAS  PubMed  Google Scholar 

  16. Isaacs, J.T. Cellular factors in the development of resistance to hormonal therapy. In Bruchovsky, N., Goldie, J. (eds). Drug and Hormone Resistance in Neoplasia. Vol. 1, CRC Press, Boca Raton, Inc., pp 139–156, 1982.

    Google Scholar 

  17. Ellis, W. J., Isaacs, J.T. Effectiveness of complete vs partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic carcinomas. Cancer Res., 45:6041–6050, 1985.

    CAS  PubMed  Google Scholar 

  18. Redding, T.W., Schally, A.V. Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen flutamide on the treatment of Dunning R-3327 H prostatic cancer model. The Prostate, 6:219–232, 1985.

    Article  CAS  PubMed  Google Scholar 

  19. Kung, T.T, Mingo, G.G, Siegel, M.I, Watnick, A.S. Effect of adrenalectomy, flutamide and leuprolide on the growth of the Dunning R-3327 prostatic carcinomas. The Prostate, 12:357–364, 1988.

    Article  CAS  PubMed  Google Scholar 

  20. Isaacs, J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate, 5:1–18, 1984.

    Article  CAS  PubMed  Google Scholar 

  21. Schulze, H., Isaacs, J., Senge, T. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormone therapy. J. Urol., 137:909–914, 1987.

    CAS  PubMed  Google Scholar 

  22. Isaacs, J.T. Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Res., 49:6290–6294, 1989.

    CAS  PubMed  Google Scholar 

  23. Schackney, S.E., McCormack, G.W., Curhural, G.J. Growth rate patterns of solid tumours and their relation to responsiveness to therapy. Ann. Intern. Med., 89:107–113, 1978.

    Google Scholar 

  24. Tubiana, M., Malaise, E.P. Growth rate and cell kinetics in human tumours: some prognostic and therapeutic implications. In Symington, R., Carter, R.L. (eds.), Scientific Foundations of Oncology, Year Book Med Publishers, pp 126–136, 1975.

    Google Scholar 

  25. Helpap, B., Steins, R., Bruhl, P. Autoradiographic in vitro investigations of prostatic tissue with C-14 and H-3 thymidine double labelling method. Beitr Pathol Anta Allgem Path., 151:65–72, 1974.

    CAS  Google Scholar 

  26. Meyer, J.S., Sufrin, G., Martin, S.A.S. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol., 128:1353–1356, 1982.

    CAS  PubMed  Google Scholar 

  27. Isaacs, J.T. Antagonistic effect of androgen on prostatic cell death. The Prostate, 5:545–558, 1984.

    Article  CAS  PubMed  Google Scholar 

  28. Wyllie, A.H., Kerr, J.F.R., Currie, A.R. Cell death: the significance of apoptosis. Int Rev Cytol., 68:251–306, 1986.

    Article  Google Scholar 

  29. Kerr, J.F.R., Wyllie, A.H., Currie, A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Brit J Cancer., 26:239–257, 1972.

    Article  CAS  PubMed  Google Scholar 

  30. Bowen, I.D., Lockshin, R.A. Cell death in biology and pathology. London: Chapman and Hill. 1981.

    Book  Google Scholar 

  31. Wyllie, A.H. Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature, 284:555–556, 1980.

    Article  CAS  PubMed  Google Scholar 

  32. Wyllie, A.H., Kerr, J.F.R., Macaskill, I.A.M., Currie, A.R. Adrenocortical cell deletion: the role of ACTH. J. Pathol., 111:85–94, 1973.

    Article  CAS  PubMed  Google Scholar 

  33. Umansky, S.R., Korol B.A., Nelipovich, P. A. In vivo DNA degradation in thymocytes of-irradiated or hydrocortisone-treated rats. Biochim Biophys Acta., 655:9–17, 1981.

    Article  CAS  PubMed  Google Scholar 

  34. Cohen, J.J., Duke, R.C. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol., 132:38–42, 1984.

    CAS  PubMed  Google Scholar 

  35. Wyllie, A.H., Morris, R.G., Smith, A.L., Dunlop, D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol., 142:67–77, 1984.

    Article  CAS  PubMed  Google Scholar 

  36. Compton, M.M., Cidlowski, J.A. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology, 118:38–45, 1986.

    Article  CAS  PubMed  Google Scholar 

  37. Kyprianou, N., Isaacs, J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122:552–562, 1988.

    Article  CAS  PubMed  Google Scholar 

  38. Kyprianou, N., English, H.F., Isaacs, J.T. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate, 13:103–118, 1988.

    Article  CAS  PubMed  Google Scholar 

  39. English, H.F., Kyprianou, N., Isaacs, J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate, 15:233–250, 1989.

    Article  CAS  PubMed  Google Scholar 

  40. Kerr, J.F.R., Searle, J. Deletion of cells byapoptosis during castration-induced involution of the rat prostate. Virchows Archiv B., 13:87–102, 1973.

    CAS  Google Scholar 

  41. Lesser, B., Bruchovsky, N. The effects of testosterone, 5-dihydrotestosterone and adenosine 3’,5’-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta., 308:426–437, 1973.

    Article  CAS  PubMed  Google Scholar 

  42. Lee, C. Physiology of castration-induced regression of the rat prostate. Prog Clin Biol Res., 75A:145–159, 1982.

    Google Scholar 

  43. Sanford, M.L., Searle, J.W., Kerr, J.F.R. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology, 16:406–410, 1984.

    Article  Google Scholar 

  44. Stanisic, T., Sadlowski, R., Lee, C., Grayhack, J.T. Partial inhibition of castration-induced ventral prostate regression with actinomycin D and cycloheximide. Invest Urol., 16:19–22, 1978.

    CAS  PubMed  Google Scholar 

  45. Lee, C., Sensibar, J. A. Protein of the rat prostate: Synthesis of new proteins in the ventral lobe during castration-induced regression. J. Urol., 138:903–908, 1985.

    Google Scholar 

  46. Saltzman, A.G., Hiipakka, R.A., Chang, C., Liao, S. Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate. J. Biol. Chem., 262:432–437, 1987.

    CAS  PubMed  Google Scholar 

  47. Montpetit, M.L., Lawless, K.R., Tenniswood, M. Androgen repressed messages in the rat ventral prostate. The Prostate, 8:25–36,1986.

    Article  CAS  PubMed  Google Scholar 

  48. Buttyan, R., Zaker, Z., Lockshin, R., Wolgemuth, D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol., 2:650–657, 1988.

    Article  CAS  PubMed  Google Scholar 

  49. Kyprianou, N., Isaacs, J.T. Expression of transforming growth factor-in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol, 3:1515–1522, 1989.

    Article  CAS  PubMed  Google Scholar 

  50. Connor, J., Sawdzuk, I.S., Benson, M.C., Tomashersky, P., O’Tool K.M., Olsson, C.A., Buttyan, R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. The Prostate, 13:119–130, 1988.

    Article  CAS  PubMed  Google Scholar 

  51. Nicotera, P., McConkey, D.J., Jones, D.P., Orrenius, S. ATP stimulates Ca2+ uptake and increasesthe free Ca2+ concentration in isolated rat liver nuclei. Proc Natl Acad Sci USA, 86:453–457, 1989.

    Article  CAS  PubMed  Google Scholar 

  52. Jones, D.P., McConkey, D.J., Nicotera, P., Orrenius, S. Calcium-activated DNA fragmentation in rat liver nuclei. J. Biol Chem., 264:6398–6403, 1989.

    CAS  PubMed  Google Scholar 

  53. Viskochil D.H., Perry, S.T., Lea, D.A., Stafford, D.W., Wilson, E.M., French, F.S. Isolation of two genomic sequences encoding the mr-1400 subunit of rat prostatein. J. Biol Chem., 258:8861–8866, 1983.

    CAS  PubMed  Google Scholar 

  54. Seto, S., Carrera, C.J., Kubota, M., Wasson, D.B., Carson, D.A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin Invest., 75:377–383, 1985.

    Article  CAS  PubMed  Google Scholar 

  55. Carson, D.A., Seto, S., Wasson, D.B., Carrera, C.J. DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res., 164:273–281, 1986.

    Article  CAS  PubMed  Google Scholar 

  56. Berger, N.A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiation Res., 101:4–15, 1985.

    Article  CAS  PubMed  Google Scholar 

  57. Berger, N.A., Berger, S.J., Sudar, D.C., Distelhorst, C.W. Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells. J. Clin Invest., 79:1558–1563, 1987.

    Article  CAS  PubMed  Google Scholar 

  58. McKeehan, W.L., Adams, P.S. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type. In Vitro Cell Dev Biol., 24:243–246, 1988.

    Article  CAS  Google Scholar 

  59. Kyprianou, N., Isaacs, J.T. Identification of a cellular receptor for transforming growth factor in rat ventral prostate and its negative regulation by androgens. Endocrinology, 123:2124–2131, 1988.

    Article  CAS  PubMed  Google Scholar 

  60. van Steenbrugge, G.J., Groen, M., Romijn, J.C., Schroder, F. Biological effects of hormonal treatment regimens on a transplantable human prostate tumor line (PC-82). J. Urol., 131:812–817, 1984.

    PubMed  Google Scholar 

  61. Kyprianou, N., Isaacs, J.T. Thymine-less death in androgen-independent prostatic cancer cells. Biochem Biophys Res Comm., 165:73–81, 1989.

    Article  CAS  PubMed  Google Scholar 

  62. Tucker, R.W., Meade-Cobun, K., Loats, H. Measurement of free intracellular calcium (Cai) in fibroblasts. Digital image analysis of Fur a 2 fluorescence. In Fiskum, G. (ed), Plenum Publ Corp, pp 239–248, 1989.

    Google Scholar 

  63. Bettuzzi, S., Hiipakka, R.A., Gilna, P., Liao, S. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J., 257:293–296, 1989.

    CAS  PubMed  Google Scholar 

  64. Sylvester, S.R., Skinner, M.K., Griswold, M.D. A sulfated glycoprotein synthesized by Sertoli cells and by epididymal cells is a component of the sperm membrane. Biol Reprod., 31:1087–1101, 1984.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James Buchanan Brady Urological Institute, The Johns Hopkins Oncology Center, The Johns Hopkins Medical Institution, Baltimore, MD, 21205, USA

    Natasha Kyprianou, Paula Martikainen & John T. Isaacs

Authors
  1. Natasha Kyprianou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Martikainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John T. Isaacs
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Office of Scientific Administration, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

    James P. Karr Ph.D. (Chief) (Chief)

  2. The Johns Hopkins Hospital and University, Marburg Building, 600 North Wolfe Street, Baltimore, MD, 21205, USA

    Donald S. Coffey Ph.D. (Professor of Urology, Oncology and Pharmacology) (Professor of Urology, Oncology and Pharmacology)

  3. Department of Growth Biochemistry and Physiology, Merck, Sharpe and Dohme Research Lab, 126 East Lincoln Avenue, Rahway, NJ, 07065, USA

    Roy G. Smith Ph.D.

  4. Mayo Clinic, Guggenheim-4 200 First Street, SW, Rochester, MN, 55905, USA

    Donald J. Tindall Ph.D. (Professor of Urologic Research) (Professor of Urologic Research)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kyprianou, N., Martikainen, P., Isaacs, J.T. (1991). Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells. In: Karr, J.P., Coffey, D.S., Smith, R.G., Tindall, D.J. (eds) Molecular and Cellular Biology of Prostate Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3704-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3704-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6647-8

  • Online ISBN: 978-1-4615-3704-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation